Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC
Status:
Completed
Trial end date:
2021-06-06
Target enrollment:
Participant gender:
Summary
This is a single-arm non-interventional study (NIS) to evaluate the effectiveness, safety and
quality of life (QoL) in patients with advanced NSCLC receiving the combination of
nab-paclitaxel and carboplatin as first line palliative therapy in a real life setting.